Companies in #Diffuse Large B-Cell Lymphoma (DLBCL)
Found 2 companies operating in this sector.
ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.
Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company developing and commercializing novel therapies for cancer and other diseases, with its lead asset XPOVIO (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved by the FDA for multiple oncology indications including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma. The company is also advancing selinexor in myelofibrosis through its XPORT-MF-034 Phase 3 trial and exploring next-generation SINE compounds. In May 2026 stockholders approved an amendment to the 2022 Equity Incentive Plan (3.0M new shares added; Form 8-K May 21, 2026), and on July 13, 2026 the Board implemented a 2026 Leadership Cash & Equity Retention Program covering all named executive officers and the CFO using performance-based restricted stock units with a market-cap vesting hurdle (Form 8-K July 17, 2026, accession 0001193125-26-307964).